Amicus Therapeutics: Chaperones Work

GeneWiz: Outsourcing to China

Speedy Tests Expand Access Bio

Semorex: Weapon Detector

At Deer Park Drive: Pharma Services

Pelican’s Testing Lab

Spaces Available

Deaths

Corrections or additions?

This article by Barbara Fox was prepared for the May 14, 2003 edition of U.S. 1 Newspaper. All rights reserved.

Leading Edge R&D: Pharmas & Biotechs

Most of the young research and development companies

on the Princeton scene are in the pharma/biotech areas, and the six

new companies profiled below offer some intriguing demographics. Three

of them — AstaTech, GeneWiz, and Pelican — are technical service

firms, meaning that they do analyses for larger companies. The first

two were founded by Chinese Americans who outsource work economically

to their native land.

The other three companies — Semorex, Amicus Therapeutics, and

Access Bio — are presenting their own new technologies. Semorex

was founded in Israel, the intellectual property of Amicus Therapeutics

was developed first in Japan, and Access Bio’s founder is from Korea.

All six companies reside in incubator-like spaces, at either the state-sponsored

"post incubator" space that comes furnished at Technology

Center of New Jersey, the laboratory complex built by the New Jersey

Economic Development Authority on Route 1 South in North Brunswick,

or the private one at Harold Kent’s Princeton Corporate Plaza on Deer

Park Drive.

Top Of Page
Amicus Therapeutics: Chaperones Work

Say "chaperone" and one thinks of class trips

with parents herding kindergartners into a museum or a zoo. But a

firm at the Technology Center of New Jersey, Amicus Therapeutics,

uses the term chaperone to describe pharmacological solutions to genetic

disorders.

Amicus is developing new therapies to treat genetic diseases, particularly

orally active drugs that are simple and convenient to administer.

Occupying four of the furnished spaces in the Commercialization Center

at the Technology Center of New Jersey, it is one of the new bright

stars on the pharma/biotech horizon. The firm has 10 employees and

hopes to hire 20 more people, including a CFO and chief medical officer,

by the end of the year, says CEO Norman Hardman. He expects to raise

$20 to $23 million by the end of the summer and begin clinical trials

next year.

Amicus can create "pharmacological chaperones" to help misplaced

proteins get to the appropriate site of activity and perform their

appropriate biological function. These misplaced or "misfolded"

proteins are the cause of some diseases of genetic origin. When the

proteins can "fold" correctly, they can bypass the cell’s

protein quality control mechanism, get to the right place, and perform

effectively, says Hardman.

"A protein is a long chain of amino acids, like beads on a string,"

explains Hardman. "It folds in a certain shape, and the shape

determines how the protein functions. If it gets changed by mutation,

it doesn’t fold the way it should, so it doesn’t function. We want

to correct that by a small drug that interacts with the protein so

it folds in the right way."

"As far as we know, we are the first commercial enterprise that

is focused on commercializing pharmacological chaperone technology.

Institutions currently working on pharmacological chaperone technology

are the University of California at San Francisco, the Scripps Institute,

and some scientists in the United Kingdom, but they are not corporately

focused," Hardman says.

Co-founder Jian-Qiang Fan, a graduate of Kagoshima University with

a PhD from Kyoto University, did a post-doctoral fellowship at Johns

Hopkins University. But he was back in Japan, working on lysosomal

storage diseases, when he discovered that when a small molecule drug

is bound to the protein in a particular way, the protein will work

more efficiently. At an academic meeting he met his future mentor,

Robert J. Desnick, an export on lysosomal storage diseases, and Desnick

— seeing the possibilities — brought Fan from China to Mount

Sinai School of Medicine. Fan paid for the patent filing, but Mount

Sinai helped him pursue the patent and has an equity stake in the

firm.

The consequences of protein misfolding have been known for some time,

but being able to develop drugs based on correcting the misfolding

is new, says Hardman.

Hardman grew up in north of England, near Manchester,

the same part of England as David Palling, the company’s director

of clinical development. His parents had a bakery, and his father

had also been a tailor. With good grades he earned his place in an

academic secondary school, where he says, "I excelled more than

I had ever done — I became top of the class and it tasted good.

I never looked back." An amateur pianist who plays Beethoven,

Chopin, and Satie, he has the theory that scientists are like artists

because both are passionate about their work.

He says his parents taught him to think independently, "to believe

that you don’t need to know everything about everything, that you

can figure something out along the way." He met his wife, a molecular

immunologist, when they were both studying in Scotland, and they live

in Cranbury with their two daughters, ages 10 and 12, who are being

home schooled.

A chemistry major at the University of London, Class of 1967, Hardman

earned his doctorate in biochemistry from the University of Manchester.

He worked for Ciba-Geigy Pharmaceuticals in Switzerland and the UK,

and he led its antibody engineering program from 1986 to 1993. He

spent a year as head of R&D at Novartis in Horsham, UK, and then moved

to Texas-based GeneMedicine, where as president and COO he helped

set up the company’s 1999 merger with California-based Megabios Corporation.

Then he was COO of Onyx Pharmaceuticals, also based in California,

and most recently was senior vice president of technology at Enzon

Inc., where he expanded the firm’s single-chain-antibody pipeline.

Before he took the Amicus job he was on the board and had helped to

put the business plan together and recruit the management team.

Venture capitalist Ronald W. Lennox, chairman of the Amicus board,

had been with Hancock Venture Partners and is now with Collinson Howe

& Lennox (CHL) in Stamford, Connecticut. Ten of the 16 companies he

founded at Hancock have gone public.

David Palling, vice president of pre-clinical development, has undergraduate

and graduate degrees from the University of London, King’s College,

and did postdoctoral work at Brandeis. Most recently he was vice president

of worldwide assay R&D at Ortho Clinical Diagnostics, a Johnson &

Johnson Company, where he supervised new product development in transfusion

medicine and immunodiagnostics. He has also been senior director for

pharmaceutical development at Johnson & Johnson Pharmaceutical Research

and Development and had worked at Hoffman-LaRoche.

"In smaller companies you can afford to be more nimble," says

Hardman, telling how he is working with clinical research organizations

(CROs) on the initial stages of his clinical development plan. Amicus

plans for its first product to be used by patients in the first quarter

of next year. Then it will begin to get attention from larger companies

that are active in similar technology areas, such as Genzyme in Boston

and Biomarin in Marin County, California.

Another advantage to being small is that small organizations can afford

to look at the opportunities offered by "orphan" diseases,

with fewer than 100,000 patients in the United States. "If you

are the first in the class to move forward, you get seven years protection,

once you have the drug on your market. And if your molecule is giving

considerable perceived medical benefit, you can get fast track designation,

which means early evaluation of your drug for approval," says

Hardman.

For deals with larger firms, Amicus focuses its partnering efforts

on the front end, on helping academic scientists work on exploratory

programs in areas such as cystic fibrosis. "If we get to the point

where we have an application in a larger therapeutic area, then those

are the deals we would partner with a larger company."

Hardman is talking to a half-dozen venture capital companies and by

mid year he hopes to have second stage funding, $23 million for the

next two years. Roughly two-thirds of that money would be used for

clinical trials and 20 percent for subsidizing research in academic

laboratories, the rest for infrastructure.

"Even with a small company we could work on orphan drugs without

partnering, versus developing a drug for large markets that require

$4 to $5 million to get the drug to market," says Hardman.

CHL has contributed $2.5 million and currently owns about half of

the company, and the two founding scientists "have a considerable

stake," says Hardman.

The company started in incubator space at Mt. Sinai and moved to Columbia

University in the Audubon incubator, where one of its current neighbors

— GeneWiz — was also staying. Andy Schiffer of Cushman & Wakefield

helped find the four laboratories and four offices that Amicus occupies

in the post-incubator facility at the NJEDA’s Technology Center of

New Jersey. "We moved in last August and will probably renew until

we find our permanent facility," says Hardman.

"Unlike some new technology companies we are already developing

drugs. The beauty is, we can keep our options open," says Hardman.

"We have to plan to build the business as far as we can see in

the distance, and we can also see alternatives to that, based on how

the interest in the company might develop."

Amicus Therapeutics, 675 Route 1 South, Technology

Center of New Jersey, North Brunswick 08902. Norman Hardman, CEO.

732-745-9977; fax, 732-745-9769. Home page: www.amicustherapeutics.com

Top Of Page
GeneWiz: Outsourcing to China

Steve Sun and Amy Liao are Chinese American scientists

who started their successful pharmaceutical service firm, GeneWiz,

three years ago and moved to the Technology Center of New Jersey (TCNJ)

last year. Sun, who is living his entrepreneurial dream, plans to

tap economical offshore labor by opening a branch in China, which

is now open to such opportunities. "At the time I left China I

could not decide my future myself," says Sun.

A molecular biology contract research company, GeneWiz specializes

in DNA sequencing, cloning, and protein expression services. Its services

range from simple sequencing (a commodity product that costs $16 per

reaction) to big projects that can cost hundreds of thousands of dollars.

Its clients are researchers at academic, commercial, and government

institutions.

With six full-time workers, GeneWiz is growing — it just posted

two new scientist jobs. "We are the most established company in

the corridor from North Carolina to Boston, and as far as we know

we are the only one doing these services in New Jersey," says

Sun. "Most of our competitors are in Texas, Illinois, and California."

Sun met Liao in Beijing, where both were going to school, and they

met again at Columbia University. Both are married and live near Edison.

Sun’s wife is a neurobiologist who works at Columbia, and they have

a school-aged son and daughter. His mother, who is a retired obstetrician,

lives with them. Liao’s husband works for Lucent, and they have a

school-aged son.

Liao went to Nankai University in Tianjin and earned her master’s

degree at Tsinghua University, where Sun did both his undergraduate

and master’s degrees. Liao got her doctor’s degree at State University

of New York in Stony Brook, and did post doctoral study at Columbia.

Sun earned his PhD at Columbia and did post doctoral work in molecular

neurobiology at Rockefeller University and Howard Hughes Medical Institute.

"I was working at Rockefeller for three years, considering my

next career move, when I decided to be an entrepreneur, to see what

we can achieve that way," says Sun.

"Now it is possible to be an entrepreneur in China," says

Sun. His high school friend, in fact, had started his own company

in 1995 and helped Sun get the substantial amount of money he needed

for equipment. The friend’s firm, Freeman International, makes intermediates,

a pharmaceutical raw material, that Sun was able to import, store,

and sell — to raise seed capital for GeneWiz.

Sun started the business in 1999 on Long Island and moved to Audubon

Technology Center in Manhattan for the second and third years. At

this state-sponsored incubator near Columbia University, it had just

900 square feet, not enough space for the growing company. Matt Malatich

of CB Richard Ellis represented Sun in finding the space in the Commercialization

Center at the Technology Center of New Jersey (TCNJ).

TCNJ is supposed to be a synergistic place, where the work of one

tenant can help another. Such synergy actually happened, says Sun,

with GeneWiz. When he moved into two units of the Commercialization

Center, the EDA officials introduced him to George Matcham, senior

vice president of Celgene in charge of its agricultural subsidiary,

Celgro. Now Celgro is Genewiz’s client.

Genewiz’s client profile includes big pharmaceuticals such as Merck,

Pfizer, Novartis, and Schering, plus biotech companies "all over

the map," he says, such as Genentech in California, and academic

clients at Columbia, Yale, Harvard, and NIH. Many commercial clients

are in New Jersey. "Here it is much easier for us to visit them,

and they know we are in the neighborhood if they need to visit us."

Conversely, most of his former neighbors in the Audubon incubator

regret his leaving, says Sun. "Now they can’t come next door and

drop their samples. They have to pay for overnight delivery."

His marketing plan: "Scientists come to us because they need our

services, or we get referrals from colleagues, the Internet, or our

ads in trade journals. We also visit the laboratories to find out

what they need, and we have a sales rep, Ed Harris."

To access the economical human resources in China, he had planned

to set up an operation there later this year but, because of the SARS

outbreak, that will be delayed. "We have our own research component

that we want to develop also," he says. "And I want to expand

our services into forensic ID and into the consumer market — and

into diagnostics and personalized medicine. We have the expertise,

and I see that genetic medicine is on the horizon."

"I am not against going public or being purchased but that is

not the goal. I want to focus on building our business. As an entrepreneur,"

Sun says with enthusiasm, "the sky is the limit."

GeneWiz, 675 Route 1 South, Technology Center of

New Jersey, North Brunswick 08902. Steve Sun, president. 732-828-8996;

fax, 732-828-8790. Www.GeneWiz.com

Top Of Page
Speedy Tests Expand Access Bio

Access Bio is a good example of how TCNJ’s Commercialization

Center is supposed to work. Founded by Yung Choi, a native of Korea,

Access Bio was one of the earliest tenants of the incubator (U.S.

1, June 26, 2002). Now it has run out of space and will expand from

800 square feet at TCNJ to 15,000 square feet, one-fourth of a new

building at Brunswick Business Park, 2033 Route 130 in South Brunswick.

It had six people last year and has added three more.

Not only has Choi filed for a patent on his protein chip technology

for DNA diagnostics but last winter he received a $63,000 Small Business

Innovation Research grant from the U.S. Department of Defense for

early diagnosis of scrub typhus, a disease found in Asia. Caused by

a mite, untreated scrub typhus can have up to a 30 percent mortality

rate. "We developed a test kit for the SBIR program and successfully

demonstrated the feasibility of the test kit," says Choi. At the

time of last week’s telephone interview he was on deadline to submit

his application for a Phase II SBIR grant worth $700,000.

With its protein chip technology, Access Bio hopes to develop new

in-vitro diagnostic tests. "The current technology uses expensive

instruments and requires highly trained persons. We are developing

simple tests using a small instrument and simple procedures that an

emergency room nurse can do. It will give better results with good

outcome at less cost in convenient way," says Choi.

The technology for diagnostic procedures involves a drop of blood,

saliva, urine, or serum on what looks like a small plastic card, five

centimeters square. It is inserted into a small instrument, which

gives the results in one minute. The equipment costs about $3,000.

"Test results will be converted to a digital signal off the chip,"

says Choi, "enabling the quantitative test results to be transmitted

between the point of test and medical experts through the use of wireless

or on-line technology."

Access Bio’s point of care test system contrasts with one made by

I-Stat, the two decade old company with 150 people on Windsor Center

Drive (www.i-stat.com). Choi explains that I-Stat focuses on convenience

and detects elements such as urea, sodium, potassium, chloride, and

glucose. "Detecting these kinds of materials they don’t need a

very sensitive system. In contrast, our market is to detect markers

that exist at very low levels in the blood. Few companies can make

point of care ultrasensitive test system."

The son of a Presbyterian pastor, Choi studied in Seoul at the Advanced

Institute of Science and Technology (Class of 1985), and then worked

as a project manager at Samsung’s R&D center. Moving to the United

States, he worked in New Jersey before establishing his own company

in September, 2001. He searched for incubator space on the Internet,

and last year moved into the Commercialization Center at the Technology

Center in North Brunswick. He and his wife, a web designer, and her

mother live in Montgomery Township and have three school age sons.

Choi is aiming for $15 million in sales in four years. Early revenue

might come from the blood alcohol screening tests. Tests that could

provide a higher profit margin might be diagnostics for diabetes,

cardiovascular disease, and neonatal care.

"The big companies keep focusing on the $500,000 instruments and

but we are seeking to carve out a different market," says Choi,

"testing in the physicians’ office and at home, and the Third

World." Currently under development are tests for such infectious

diseases as the hepatitis C virus, complete diabetes tests, and an

alcohol test for drunk drivers.

"We don’t have any venture capital yet, but we are talking to

some big companies," says Choi.

Access Bio is not quite the perfect poster child for TCNJ. If it were

perfect, it would have elected to expand within the Tech Center, where

there is plenty of available space. "The Tech Center is fine,

but we thought the larger spaces would not be good for production.

They are more expensive, and we also wanted to design our own space,

specific to us. Our CFO drove down Route 130 and found a new building

with a very competitive price."

Access Bio Inc., 675 Route 1 South, Technology

Center of New Jersey, North Brunswick 08902. Yung Choi, CEO. 732-246-7400;

fax, 732-246-5766.

Top Of Page
Semorex: Weapon Detector

Robert Umpleby is working by himself in a unit at the

Commercialization Center at the Technology Center of New Jersey. His

company Semorex, based in Israel, believes its technology might help

with the following:

Detect chemical weapons and clean up after chemical warfare.

Treat heart disease and some cancers with a pill that

does not get absorbed into the bloodstream.

Treat GI tract diseases such as gastroesophegeal reflux,

hypercholesterolemia, colon cancer, cholestatic liver disease, and

gallstone formation.

All this is to be done with molecularly-printed polymers (MIPs)

by Semorex, which is a shortened term for "selective molecular

recognition." Semorex has filed a number of patents to protect

its high affinity MIPs.

Molecularly imprinted polymers bind to molecules selectively, and

therefore they can be useful in detecting chemical weapons, says Umpleby.

"It is feasible to have an imprinted polymer that is selective

for one molecule but it can also be designed for certain class of

molecules," says Umpleby.

A polymer, he explains, is a large molecule made up of smaller repeating

molecules — the same molecule linked to itself over and over again,

as in plastic and rubber. Because of the physical and chemical properties

of polymers, it is difficult to work with them in the usual ways,

using small molecules. "Polymers can have properties that small

molecules by themselves don’t have," says Umpleby.

"Imprinted polymers are designed to bind with a specific molecule

or class of molecules. The polymer is made in the presence of the

target molecule. To make an imprinted polymer, you put the target

molecule in with monomers (the type of small molecule used to construct

a polymer). By judiciously selecting the monomers you can create a

polymer that is imprinted with the target molecule and convert the

monomer mixture into a polymer by using heat or ultraviolet radiation."

Semorex says its MIPs can work at lower concentrations and are more

chemically stable than natural antibodies. Also they may be manufactured

with less cost and more flexibility.

Its sensors can detect individual chemical warfare agents in water,

soil and air, and distinguish them from pesticides and related commercial

products which might be found in a normal environment. The MIPs might

also help find chemical toxins in the human body, help protect people

before a chemical attack, and be used with clean-up systems following

a chemical warfare attack.

The first generation of MIPs can selectively bind to toxins linked

to the onset of heart disease and several major cancers. Development

of these polymers is expected to facilitate new treatments for these

diseases, through the use of non-absorbable pills that cannot enter

the bloodstream. Another MIP can selectively remove toxic bile acids

in the GI tract, to treat patients with gastro-esophageal reflux disease

(GERD).

Umpleby grew up in Erie, Pennsylvania, where his father was an industrial

engineer at a steel forging company. Umpleby stayed in Erie to earn

an undergraduate chemistry degree from Gannon University and MBA from

Gannon. He had an accounting job in Pittsburgh before going to the

University of South Carolina to get his PhD in organic chemistry,

graduating last year. For this position he answered an ad placed in

a journal for molecular imprinting "but one of the founders had

already been in contact with my advisor at USC."

Founders are Bernard Green, a pharmaceutical chemist and pioneer in

catalytic antibody research at the Hebrew University of Jerusalem,

and CEO Morris Priwler, an Australian attorney and biotech entrepreneur.

Guenter Wulff, a leader in the field of molecularly imprinted polymers,

is on the scientific advisory board, as are two officers of Celgene

Corporation, Sol J. Barer and Jerome B. Zeldis, who recommended TCNJ’s

space.

The company was founded in 2001, and though Umpleby is working by

himself in the incubator, he expects to have the company of two or

three other scientists by year’s end.

Semorex, 675 Route 1 South, Technology Center of

New Jersey, North Brunswick 08902. Robert Umpleby, research chemist.

732-545-7070; fax, 732-745-7270. Www.semorex.com

Top Of Page
At Deer Park Drive: Pharma Services

Paul Guo is living out his version of the American entrepreneurial

dream. He grew up on a farm in northeast China, earned his master’s

degree in Canada, and now owns AstaTech, a pharmaceutical service

laboratory that outsources much of its work to its economical offshore

lab in China. AstaTech does custom synthesis/manufacture and product

development.

With 11 employees at Deer Park Drive plus the 40-person operation

in Chengdu, China, AstaTech draws pharmaceutical clients from North

America, Europe, and Japan. "In China they do basic research and

light production. Here we do the marketing, customer service, research

and process development, and custom synthesis," says Guo. "It

is a challenge."

Guo did his undergraduate degree in China and his master’s degree

at the University of Manitoba. He came to the United States in 1992

to work for an Eastman Kodak company in Pennsylvania and was a bench

scientist at Bristol-Myers Squibb on Route 206 before starting his

own firm in 1999. He and his wife, Rona, a scientist who also works

for the company, are naturalized citizens living in Hopewell with

their teenage daughter.

"We make the unique building blocks, advanced intermediates for

drug discovery," he says. "An intermediate requires 5 to 10

steps, with the first three steps made in China, and we make the rest."

The company has devised more than 1,000 unique drug-related products

that were synthesized in its own laboratories, kilo-lab and pilot

plants. AstaTech also collaborates with four other manufacturing companies

in China to be produce quantities of materials. One order might be

worth from $500 to $10,000.

"For our name, we took the first four letters of an elemental

chemical, astatium," says Guo, who started small, borrowing money

from friends, and commissioning a website from a friend. How big does

he want the company to grow? "As big as I can," says Guo.

Astatech, 1 Deer Park Drive, Suite C, Monmouth

Junction 08852. Paul Guo. 732-355-1000; fax, 732-355-1122. Home

page: www.astaath.com

Top Of Page
Pelican’s Testing Lab

John Fiorino moved his commercial analytical testing

laboratory from Lakewood to Princeton Corporate Plaza to acquire better

laboratory space. His company, Pelican Analytics LLC, is a contract

analytical chemistry laboratory that provides consulting and analytical

services to the pharmaceutical, chemical, specialty metals, and energy

industries.

Formed in 1999, Pelican Analytics focuses on determining precious

metals and analyzing materials such as high value catalysts and high

purity plastics for the types and amounts of metals that they contain.

"Our clients are largely specialty companies interested in the

highest accuracy, or trace and ultra trace elements," says Fiorino.

Fiorino’s wife of 31 years will work with him in the firm. With a

PhD in analytical chemistry from the University of Florida, she worked

at Bell Labs in materials science, batteries, corrosion and analytical

chemistry, and she has also been a product manager for the telecommunications

equipment. They live in Bridgewater with their two Shetland sheepdogs.

Fiorino grew up in Rochester, New York, graduated from Rochester Institute

of Technology in 1962, and has a PhD from Iowa State. He worked for

such companies as Kodak, Exxon, and Degussa, and he taught analytical

chemistry at Virginia Polytech, and the University of Florida.

He left Degussa, a German firm, to found this three-person firm. "I

have consulted for years, and the consulting has almost always had

an analytical component. The need and expertise was there — and

I couldn’t think of retiring. This is the most kind of fun a person

can have," says Fiorino.

To find his space, he did extensive networking. "We were offered

a shot at a space in Newark, but the environment here and the space

here was excellent," he says.

Pelican Analytics LLC, 11 Deer Park Drive, Suite

203, Monmouth Junction 08852. John A. Fiorino, director of technology.

732-274-2600; fax, 732-274-0800. Home page: www.PelicanAnalytics.com

Top Of Page
Spaces Available

The NJEDA’s Technology Center of New Jersey has 146,000

square feet of empty space. In addition to the tenants noted above,

the lineup includes Commercialization Center tenants Ortec International,

Aeropharm (now known as Kos), and Chromocell, plus such big companies

as Merial, Celgro, and Cambrex. Four of the 17 800-square foot laboratories

are available, as are 146,000 square feet of technology space in two

buildings.

In contrast, the private landlord who owns Princeton Corporate Plaza

on Deer Park Drive has 250,000 square feet of R&D space that is mostly

leased and is building more. "Most of our R&D companies rent about

5,000 square feet, spaces that have been designed specifically for

their needs," says Harold Kent, the architect who designed the

first buildings on Deer Park Drive in 1988. "There is a lot of

synergy between the tenants — they exchange ideas and equipment."

Because most of the smaller tenants do want to expand, Kent is building

60,000 new square feet now. And because he wants to keep the pipeline

full, he will set up his own incubator in 10,000 square feet that

used to belong to Gold’s Gym (the fitness center that moved across

the street). By this summer there will be a place for 10 companies

to rent 1,000-foot fully furnished labs.

Transave Inc., which works on drug delivery for lung disease, can

be considered a poster child for Kent. Founded in 1997, it had 2,500

square feet in 2000, and with 17 full-timers recently expanded to

10,000 square feet. It offers inhalation therapeutics as an improvement

on injectables for treating lung disease because they cost less, provide

higher drug levels, and are easier to use. Transave’s lipid complexes

and liposomes can be released as a nebulized spray, a dry powder,

or an aerosol. Theradex, the firm at 14 Washington Road that manages

90 percent of the cancer trials in the United States, is in charge

of Transave’s clinical trials. After these trials, which should take

12 to 18 months, Transave will start trials on its anti-infective

drug.

Transave CEO Frank Pilkiewicz, who has raised nearly $16 million

in venture capital, will share the secrets of success on Friday, May

16, at 8 a.m. and 1 p.m. when Silicon Garden Angels hosts a Life and

Info Sciences venture capital and angels fair at the New Jersey Hospital

Association conference center (732-873-1955).

"We raised $12 million in second round funding and will use that

money to take our product through clinical studies," says Pilkiewicz.

Among his new investors is Sycamore Ventures at 5 Vaughn Drive. Leading

the second round were include Easton Hunt Capital Partners from New

York and ABN AMRO Capital from the Netherlands. Also CDIB Bioscience

of Taiwan plus first round investors Techno Venture Management (TVM)

of Boston and Munich and Musket Research Associates of Boston.

Says Pilkiewicz: "Happy is not the word, I’m ecstatic."

Transave Inc., 11 Deer Park Drive, Suite 117, Monmouth

Junction 08852. Claire Strupinsky, manager of corporate administration.

732-438-9434; fax, 732-438-9435. Www.transaveinc.com

Top Of Page
Deaths

David T. Sheppard 30, on May 2. He worked at Petsmart

at Nassau Park.

Edward A. Dowey Jr., 85, on May 5. He was professor emeritus

at Princeton Theological Seminary.

Peter Sannino, 82, on May 11. He owned Sannino Plumbing

and Heating Contractors.


Next Story


Corrections or additions?


This page is published by PrincetonInfo.com

— the web site for U.S. 1 Newspaper in Princeton, New Jersey.

Facebook Comments